The SEC has charged Zymergen Inc., a synthetic biology company, with misleading investors ahead of its $3 billion IPO. The charges include providing false information about its market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline. Zymergen has agreed to settle the charges by paying a $30 million penalty. The SEC's involvement underscores the seriousness of the allegations.